Last edition
News about "Numab Therapeutics"
Johnson and Johnson to Obtain Rights to Clinical-Stage Bispecific Antibody
Johnson & Johnson has signed a definitive deal with Numab Therapeutics, to acquire from Numab’s shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26.
Numab Therapeutics | 30/05/2024 | By Aishwarya | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members